Background
Idiopathic pulmonary fibrosis (IPF) is a progressive fibro-proliferative disorder of unknown etiology, with no effective treatment regimen, and a median survival of just 3-5 years following diagnosis [1] . Pulmonary Hypertension (PH) often complicates IPF and is associated with higher mortality. Augmentation of endogenous natriuretic peptide (NP) stimulated cGMP, using a neutral endopeptidase inhibitor (NEPi) in combination with a phosphodiesterase 5 inhibitor (PDE5i), synergistically prevents pathogenesis in a hypoxic model of PH [2] . Herein, we assessed the efficacy of this novel NEPi/ PDE5i combination therapy in a model of pulmonary fibrosis.
Methods
Littermate wild-type (WT) and NP receptor-A knockout (NPR-A KO) mice (male; 20-25g; C57BLK6 background) were instilled with saline (control) or Bleomycin (Bleo; 1mg/kg) in the absence or presence of the PDE5i sildenafil (30mg/kg/day; p.o.) or the NEPi ecadotril (60mg/kg/day; p.o.). Haemodynamic and morphological parameters were measured 14 days post Bleo administration.
Results
Bleo treatment caused a significant rise in right ventricular systolic pressure (RSVP) in WT mice that was not reduced by either sildenafil or ecadotril alone, but significantly inhibited by the combination (Figure 1 
Conclusion
The NEPi/PDE5i combination is effective in ameliorating both the haemodynamic aberrations and fibrotic lung disease in this model. This beneficial pharmacodynamic activity depends on the bioactivity of NPs, which represent an endogenous protective mechanism limiting disease progression. This work substantiates the therapeutic potential of manipulating NP and cyclic GMP signalling for PH and IPF.
* Correspondence: r.baliga@ucl.ac.uk 1 Department of Pharmacology, University College London, Gower Street, London WC1E 6BT, UK Full list of author information is available at the end of the article Figure 1 Right ventricular systolic pressure (RVSP) in saline-treated mice (n=14), and Bleo-treated (n=8) animals in the absence and presence of sildenafil (SILD, n=7), ecadotril (ECAD; n=8) and combination treatment (n=9). *P<0.05 versus Bleo alone.
